Gf Fund Management 13F: Adds $21M to Eli Lilly and (LLY) Stake

Gf Fund Management boosted its stake in Eli Lilly and Company (LLY) by 18,038 shares, valued at about $46.9 million, in a filing on October 26, 2026. This increase brings the fund's total holdings to 40,491 shares.

LLY Eli Lilly and Company

$1,279.14 ▲ +18.97% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Where Eli Lilly Fits in Gf Fund Management's Portfolio

Gf Fund Management's investment in Eli Lilly now accounts for 1.1% of its overall portfolio, ranking it 24th among the fund's 616 positions.

Other Institutional Activity in Eli Lilly

On October 26, 2026, UniSuper Management increased its stake in Eli Lilly by 34,948 shares, totaling 228,947 shares worth approximately $264.9 million. Signaturefd also added 961 shares, bringing its total to 27,035 shares valued at about $31.3 million. Anderson Hoagland boosted its holdings by 860 shares, raising its total to 23,796 shares valued at approximately $31.1 million.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly's stock is currently trading around $1,279.16, which is about equal to its closing price of $1,279.14 on October 26, 2026. The shares are above their 50-day moving average by 7.8% and their 200-day moving average by 17.9%. However, they are 3.2% below the 52-week high of $1,321.21.

Recent Earnings

Eli Lilly reported trailing twelve-month revenue of approximately $79.7 billion, with a net margin of 33.5%. The company is set to announce its next earnings on October 29, 2026.

Dividend

Eli Lilly has an annual dividend rate of $6.92 per share, translating to a yield of 0.54%. The dividend payout ratio stands at 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Several insiders sold shares earlier this year, including Anat Hakim, General Counsel, who sold 5,000 shares at an average price of $1,190 on August 7, 2026, totaling approximately $5.95 million. Other sales include Donald A Zakrowski, who sold 2,000 shares for about $2.37 million, and Patrik Jonsson, who sold 6,500 shares for about $7.6 million.

Analysts Set New Price Targets

On October 21, 2026, Leerink Partners maintained its "Outperform" rating on Eli Lilly with a price target of $1,316. Prior analyst ratings have also been positive, with several firms maintaining "Overweight" ratings and targets ranging from $1,430 to $1,500.

About Eli Lilly

Eli Lilly and Company is a major player in the healthcare sector, focusing on the discovery, development, manufacturing, and marketing of pharmaceutical products globally. The company's recent growth and strong financial performance have attracted significant institutional interest.

Bottom Line

Investors will be keeping an eye on Eli Lilly's upcoming earnings report on October 29, 2026, and further developments in institutional trading. Gf Fund Management's latest increase in its stake reflects continued confidence in the company's potential.